Insulet (PODD) Rating Lowered to Hold at Zacks Investment Research
Zacks Investment Research lowered shares of Insulet (NASDAQ:PODD) from a buy rating to a hold rating in a research note published on Friday morning.
According to Zacks, “Insulet exited the second-quarter 2018 on a mixed note. We are encouraged by the year-over-year improvement in net loss and revenues on solid uptake of Omnipod system in the United States. Expanding global customer base also drove revenues. Furthermore, expanding gross margin buoys optimism. We are also upbeat about Insulet’s solid progress with respect to its four-pillar strategy. Further, the receipt of FDA nod for the company’s Omnipod DASH Insulin Management System boosts investor confidence. Insulet has been outperforming its industry over the past year. Meanwhile, management expects the shifting to direct operations in Europe to continue to mar international revenues. Moreover, Insulet is exposed to risks associated with a weaker global economy and lower reimbursement rates.”
Other equities analysts have also issued research reports about the company. BidaskClub lowered Insulet from a strong-buy rating to a buy rating in a research note on Tuesday, June 19th. Canaccord Genuity reiterated a buy rating and set a $90.00 target price on shares of Insulet in a research note on Wednesday, May 2nd. Berenberg Bank started coverage on Insulet in a research note on Friday, April 20th. They set a buy rating and a $100.00 target price on the stock. Northland Securities reiterated a buy rating and set a $100.00 target price on shares of Insulet in a research note on Friday, May 4th. Finally, Jefferies Financial Group reiterated a buy rating and set a $97.00 target price on shares of Insulet in a research note on Friday, August 3rd. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $91.94.
Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, August 2nd. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.10. The firm had revenue of $124.26 million for the quarter, compared to analyst estimates of $132.89 million. Insulet had a negative return on equity of 11.91% and a negative net margin of 3.47%. The business’s revenue for the quarter was up 13.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.13) earnings per share. equities research analysts predict that Insulet will post -0.1 EPS for the current fiscal year.
In other Insulet news, SVP Michael P. Spears sold 7,496 shares of the firm’s stock in a transaction on Wednesday, June 13th. The stock was sold at an average price of $100.00, for a total transaction of $749,600.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Michael P. Spears sold 8,071 shares of the firm’s stock in a transaction on Wednesday, May 30th. The stock was sold at an average price of $95.00, for a total value of $766,745.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,950 shares of company stock worth $2,884,036. Corporate insiders own 3.60% of the company’s stock.
A number of institutional investors have recently bought and sold shares of PODD. Pier 88 Investment Partners LLC bought a new position in Insulet during the 2nd quarter worth $184,000. First Republic Investment Management Inc. bought a new position in Insulet during the 1st quarter worth $209,000. Zeke Capital Advisors LLC bought a new position in Insulet during the 1st quarter worth $241,000. Brinker Capital Inc. bought a new position in Insulet during the 1st quarter worth $249,000. Finally, Harbour Capital Advisors LLC bought a new position in Insulet during the 2nd quarter worth $269,000.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Featured Story: Understanding Stock Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.